Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCell Pharma ABFRA:65G +8.42%48 Intrinsic Value: DCF (Dividends Based) is € as of Aug. 10, 2026. GuruFocus rates FRA:65G with a GF Score™ of 48/100 and a GF Value™ of €0.06 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 20 Biotechnology companies, NextCell Pharma AB ranks worse than 4999995% on this metric.
Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star) with dividend payments. If the company's Predictability Rank is 1-Star or Not Rated, or if the company does not pay dividend, the data will not be stored into our database.
NextCell Pharma AB's Predictability Rank is 1-Star. Thus, this page is only used for demonstration purposes and the DCF related results in the screener and portfolio will appear as zero.
The historical rank and industry rank for NextCell Pharma AB's Intrinsic Value: DCF (Dividends Based) or its related term are showing as below:
FRA:65G's Price-to-DCF (Dividends Based) is not ranked *
in the Biotechnology industry.
Industry Median: 1.61 * Ranked among companies with meaningful Price-to-DCF (Dividends Based) only.
What you need to know about Discounted Dividends model:
1. The Discounted Dividends model evaluates a company based on its future dividends distribution power
2. Dividend growth is taken into account; therefore a company with a higher dividend growth rate is worth more if everything else is the same.
3. Since we are projecting future growth, it is assumed that the company will grow at the same rate as it did during the past 10 years. Therefore this model works better for the companies with consistently steady dividends distributed.
4. The Discounted Dividends model works poorly for inconsistent dividends distributor like high growth companies.
5. Your expected return from the investment is a reasonable discount rate assumption.
6. A larger margin of safety should be required for companies with less dividends distributed.
NextCell Pharma AB Intrinsic Value: DCF (Dividends Based) Related Terms
NextCell Pharma AB Intrinsic Value: DCF (Dividends Based) Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Intrinsic Value: DCF (Dividends Based) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB Intrinsic Value: DCF (Dividends Based) Chart
For the Biotechnology subindustry, NextCell Pharma AB's Price-to-DCF (Dividends Based), along with its competitors' market caps and Price-to-DCF (Dividends Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Price-to-DCF (Dividends Based) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Price-to-DCF (Dividends Based) distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Price-to-DCF (Dividends Based) falls into.
NextCell Pharma AB Intrinsic Value: DCF (Dividends Based) Calculation
This is the intrinsic value calculated from the Discounted Dividend Model with default parameters. The calculation method is the same as Discounted Cash Flow model except adjusted dividend are used in the calculation instead of free cash flow. This is the default method of calculation with GuruFocus DCF calculator.
Usually a two-stage model is used in calculating the intrinsic value with discounted cash flow model. The first stage is called growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.
GuruFocus DDM calculator is a two-stage model. The default values are defined as:
1. Discount Rate: d = 9% A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 2.78%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.
2. Dividend Growth Rate in the growth stage: g1 = %
The Growth Rate in the growth stage is initially set as the default 10-Year Dividend Growth Rate. In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year Dividend Growth Rate. If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year Dividend Growth Rate.
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>
3. Years of Growth Stage: y1 = 10
4. Terminal Growth Rate: g2 = 4%
5. Dividends per Share: adjusted dividends per share = €. GuruFocus uses adjusted dividends per share by default to ensure that the valuation reflects the total value of the company, as the actual dividend is only a portion of the total value.
All of the default settings can be changed in the DCF calculator and the results are calculated automatically.
NextCell Pharma AB's Intrinsic Value: DCF (Dividends Based) for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: DCF (Dividends Based) of € mean?
NextCell Pharma AB (FRA:65G) has a Intrinsic Value: DCF (Dividends Based) of € as of Aug. 10, 2026. Intrinsic Value: DCF (Dividends Based) is the stock value based on a two-stage discounted dividend model. View historical data on NextCell Pharma AB and its competitors. According to the industry distribution chart, NextCell Pharma AB ranks #999999 out of 20 companies in the Biotechnology industry.
Is NextCell Pharma AB's Intrinsic Value: DCF (Dividends Based) too high?
NextCell Pharma AB's current Intrinsic Value: DCF (Dividends Based) is €. Based on the distribution chart, NextCell Pharma AB ranks #999999 out of 20 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NextCell Pharma AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Intrinsic Value: DCF (Dividends Based) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #999999 out of 20 companies for Intrinsic Value: DCF (Dividends Based). This places NextCell Pharma AB in the lower half of its industry. The industry median Intrinsic Value: DCF (Dividends Based) is 1.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: DCF (Dividends Based) for a Biotechnology company?
The median Intrinsic Value: DCF (Dividends Based) among Biotechnology companies is 1.61, based on 20 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: DCF (Dividends Based) significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: DCF (Dividends Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: DCF (Dividends Based) mean?
A high Intrinsic Value: DCF (Dividends Based) can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: DCF (Dividends Based) is the stock value based on a two-stage discounted dividend model. View historical data on NextCell Pharma AB and its competitors. For the Biotechnology industry, the median Intrinsic Value: DCF (Dividends Based) is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCell Pharma AB's current Intrinsic Value: DCF (Dividends Based) is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.09 — trading 41.7% above its estimated fair value. The current Intrinsic Value: DCF (Dividends Based) is €. NextCell Pharma AB's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: DCF (Dividends Based) calculated?
Intrinsic Value: DCF (Dividends Based) is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Intrinsic Value: DCF (Dividends Based) is € as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.09 is trading 41.7% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Significantly Overvalued.
Key valuation signals for FRA:65G:
Intrinsic Value: DCF (Dividends Based): €
GF Value™: €0.06 vs. price of €0.09 (41.7% above fair value)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
48GF Score
Get the complete analysis for FRA:65G
Intrinsic Value: DCF (Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
